TRDA's Quality Score rose 3 points on Tue, Nov 10, to -6. Buying reached its highest in 20 days (3 chart checks started).
Follow TRDA's trial news. Pro members can get an alert when Entrada Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 11.9% today, while its biotech peers are down 1.4%; no story names it yet.
Fell on Nov 5
Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.
−3Long-term trend
| Holding it back | Sales down 80% |
| Latest filing | 8-K, Nov 5 |
TodayNo story names it yet.
After its last 4 reports it closed -15.8% on average, higher 1 of 4 times.
About 3 quarters
Director Kush Parmar sold 155,255 shares on Aug 10. 8 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
TRDA is #239 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 239 |
Expected to report Thu Feb 25, before the open (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.94 a share, from $1.06.
“The decrease was primarily driven by lower preclinical costs for the Company’s Duchenne programs and lower facility-related costs.”
TRDA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease was primarily driven by cash used to fund operations.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -0.2% | -10.1% | not yet |
| Aug 5, 2026 | +3.2% | -2.5% | -2.8% |
| May 7, 2026 | -57.5% | -57.3% | -54.3% |
Sales grew in one of the last two years, to $25.4M in 2025. It lost money in 2025 after a profit in 2024.
RSI 52.1, MACD above signal, below both averages. Not scored.
One insider bought $29K across 1 filing, and 3 insiders sold $5.5M across 17 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: TRDA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
“The biotechnology and biopharmaceutical industries generally, and the neuromuscular disease field specifically, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
TRDA scores -6 today, which Breakaway calls Poor. It is #239 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 3 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TRDA scores -6 today, which Breakaway calls Poor (below zero). That is #239 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TRDA's -6.
One insider bought $29K across 1 filing, and 3 insiders sold $5.5M across 17 filings, in the last 6 months. The newest is MPM Bioventures 2018, L.P., 10% owner, who sold $1.4M on Sep 8. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.